<DOC>
	<DOCNO>NCT02987166</DOCNO>
	<brief_summary>This study pilot study evaluate high-dose conformal radiation therapy ( HDCRT ) administer combination pembrolizumab patient solid tumor .</brief_summary>
	<brief_title>HDCRT Plus Pembrolizumab Advanced Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Subjects must histologically cytologically proven advanced solid tumor malignancy palliative radiation recommend . In solid tumor pembrolizumab approve use , patient may receive pembrolizumab indicate , context protocol . In solid tumor pembrolizumab approve use , follow criterion apply : Patients must resistant least 1 prior conventional chemotherapy regimen standard care regimen , Patient must remain conventional treatment option prove provide longterm disease control , Patient decline conventional treatment option Palliative radiation therapy may recommend primary tumor and/or metastatic site accessible biopsy . At least one site disease accessible radiation multiple biopsy . Subjects may disease encompass within radiation field may know disease inside outside radiation field . Must able provide tissue 23 separate biopsy procedure complete throughout course study . A performance status 0 , 1 2 ECOG Performance Scale . Subjects must demonstrate adequate organ function . A life expectancy â‰¥ 6 month . Requires urgent treatment cytotoxic chemotherapy therapy indicate . A diagnosis immunodeficiency . A known history active TB ( Bacillus Tuberculosis ) . Known active central nervous system ( CNS ) metastases and/or carcinomatous meningitis . Subjects untreated brain metastasis patient brain metastasis retreat radiation exclude . Patients either midline shift , sign herniation ( even disease treated GK ) exclude . Subjects previously treat brain metastasis may participate provide 1 ) stable ( without clinical evidence progression ) 2 ) least 10 day CNS radiation 3 ) use steroids part treatment brain lesion least 7 day prior trial treatment . This exception include carcinomatous meningitis exclude regardless clinical stability . Active autoimmune disease require systemic treatment past 2 year . A history ( noninfectious ) pneumonitis require steroid current pneumonitis . An infection require systemic therapy . Pregnancy . HIV positivity . Evidence active Hepatitis B virus Hepatitis C virus . Significant cardiovascular disease include unstable angina pectoris , uncontrolled hypertension , uncontrolled arrhythmia , severe valvular heart disease , myocardial infarction within 6 month prior first dose study treatment . Active bleeding disorder evidence chronic acute disseminate intravascular coagulation ( DIC ) . Class III IV heart disease ( New York Heart Association classification ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>immunotherapy</keyword>
	<keyword>pembrolizumab</keyword>
	<keyword>MK-3475</keyword>
	<keyword>High-dose conformal radiation therapy</keyword>
	<keyword>HDCRT</keyword>
	<keyword>advanced solid tumor</keyword>
</DOC>